BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 20538672)

  • 21. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.
    Tobis JM; Charles A; Silberstein SD; Sorensen S; Maini B; Horwitz PA; Gurley JC
    J Am Coll Cardiol; 2017 Dec; 70(22):2766-2774. PubMed ID: 29191325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of transcatheter closure of patent foramen ovale in the evolution of migraine and role of residual shunt.
    Biasco L; Infantino V; Orzan F; Vicentini S; Rovera C; Longo G; Chinaglia A; Belli R; Allais G; Gaita F
    J Cardiol; 2014 Nov; 64(5):390-4. PubMed ID: 24713153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen.
    Fischer D; Fuchs M; Schaefer A; Schieffer B; Jategaonkar S; Hornig B; Drexler H; Meyer GP
    J Interv Cardiol; 2008 Apr; 21(2):183-9. PubMed ID: 18312307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it too early to recommend patent foramen ovale closure for all patients who suffer from migraine? A single-centre study.
    Chessa M; Colombo C; Butera G; Negura D; Piazza L; Varotto L; Bussadori C; Fesslova V; Meola G; Carminati M
    J Cardiovasc Med (Hagerstown); 2009 May; 10(5):401-5. PubMed ID: 19449455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
    Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
    Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
    Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
    EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
    Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
    BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migraine headache relief after transcatheter closure of patent foramen ovale.
    Reisman M; Christofferson RD; Jesurum J; Olsen JV; Spencer MP; Krabill KA; Diehl L; Aurora S; Gray WA
    J Am Coll Cardiol; 2005 Feb; 45(4):493-5. PubMed ID: 15708692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
    Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transseptal puncture to facilitate device closure of "long-tunnel" patent foramen ovale.
    Thompson AJ; Hagler DJ; Taggart NW
    Catheter Cardiovasc Interv; 2015 May; 85(6):1053-7. PubMed ID: 25380406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION).
    Puricel S; Arroyo D; Goy JJ; Praz F; Palhais N; Wahl A; Stauffer JC; Togni M; Berger A; Meier B; Cook S
    EuroIntervention; 2015 Jun; 11(2):230-7. PubMed ID: 24830681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
    Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
    Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
    Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
    J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of patent foramen ovale closure on visual aura without headache or typical aura with migraine headache.
    Khessali H; Mojadidi MK; Gevorgyan R; Levinson R; Tobis J
    JACC Cardiovasc Interv; 2012 Jun; 5(6):682-7. PubMed ID: 22721665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.